About Cerebellar degeneration-related protein 2
Cerebellar degeneration-related protein 2 (CDR2) is a protein
from Homo sapiens identified by UniProt accession
Q01850, 454 residues long.
MolForge cross-references it against 0 known binders and
142 disease associations.
Target properties
| Protein name | Cerebellar degeneration-related protein 2 |
| UniProt accession | Q01850 |
| Gene | CDR2 |
| Organism | Homo sapiens |
| Length | 454 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (142)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.35
- body height · score 0.23
- body weight · score 0.13
- neoplasm · score 0.08
- systemic lupus erythematosus · score 0.05
- bone density · score 0.04
- urate measurement · score 0.04
- paraneoplastic neurologic syndrome · score 0.03
- mucocutaneous lymph node syndrome · score 0.03
- cerebellar degeneration · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q01850-F1 | alphafold | PREDICTED | 74.12 | — |
Amino-acid sequence (454 residues)
MLAENLVEEF EMKEDEPWYD HQDLQQDLQL AAELGKTLLD RNTELEDSVQ QMYTTNQEQL QEIEYLTKQV ELLRQMNEQH AKVYEQLDVT ARELEETNQK LVADSKASQQ KILSLTETIE CLQTNIDHLQ SQVEELKSSG QGRRSPGKCD QEKPAPSFAC LKELYDLRQH FVYDHVFAEK ITSLQGQPSP DEEENEHLKK TVTMLQAQLS LERQKRVTME EEYGLVLKEN SELEQQLGAT GAYRARALEL EAEVAEMRQM LQSEHPFVNG VEKLVPDSLY VPFKEPSQSL LEEMFLTVPE SHRKPLKRSS SETILSSLAG SDIVKGHEET CIRRAKAVKQ RGISLLHEVD TQYSALKVKY EELLKKCQEE QDSLSHKAVQ TSRAAAKDLT GVNAQSEPVA SGWELASVNP EPVSSPTTPP EYKALFKEIF SCIKKTKQEI DEQRTKYRSL SSHS
Explore Cerebellar degeneration-related protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets